Schizophrenia is a condition comprising of both treatment and comorbidity factors that both complicate its management and present multiple unmet needs. Brilaroxazine (RP5063), a dopamine (D)/serotonin (5-HT) modulator, possesses a broad in vitro pharmacology profile against D 2/3/4 and 5-HT 1A/2A/2B/6/7 receptors, nicotinic acetylcholine (α 4 β 2 ) receptors, and the serotonin transporter. In Phase 1 and 2 clinical experience in healthy volunteers, patients with schizophrenia and schizoaffective disorder, brilaroxazine was well tolerated, with the repeated 100 mg oral dose as the maximum tolerated dose. Investigators observed no cardiometabolic, cardiovascular, prolactin, or neurologic complications. Adherence in Phase 2 was good with discontinuation rates generally less than placebo. In a Phase 2 evaluation of patients with acute exacerbations in schizophrenia and schizoaffective disorders, brilaroxazine met its primary endpoint of significance versus placebo for Total Positive and Negative Symptom Scale (PANSS) Score at Day 28 as compared to baseline. In Phase 1 multi-dose pharmacodynamic evaluation, brilaroxazine displayed clinical activity in patients with stable disease and a PANSS greater than 50, as early as Day 10 of treatment. Pharmacokinetic analyses demonstrated brilaroxazine to have a substantial and relatively rapid oral absorption, linear (dose proportional) increases in maximum concentration (C max ) and area under the curve (AUC), lack of excessive accumulation, and a relatively long terminal half-life of about 60 hours. Early clinical findings with brilaroxazine in schizophrenia and schizoaffective disorders indicate that this compound appears to be effective, well tolerated, and possess a straightforward once-daily dosing pharmacokinetic profile.
Introduction
Schizophrenia is a chronic and debilitating psychiatric syndrome affecting 1% of the world's population 1 . It is a complex disease comprised of a mix of positive and negative symptoms, along with mood disorder and cognitive impairment [2] [3] [4] . Interestingly, psychosis is also linked to several neurodegenerative disorders (NDDs), including Alzheimer disease, spectrum of Parkinson's disease, and Huntington's disease [5] [6] [7] [8] . Current pharmacologic treatment includes typical and atypical agents 9 . Tolerability issues (e.g., neuroleptic side effects with typical antipsychotics; metabolic and cardiovascular problems with atypical medications) limit compliance and effectiveness of both classes [10] [11] [12] [13] . Hence, compliance is poor, with discontinuation rates of 30-50% in the short-term management of acute patients and 42-74% in the long-term treatment 9, [14] [15] [16] [17] [18] [19] [20] [21] [22] . Also, both classes of antipsychotics fail to provide a broad spectrum of efficacy across the various symptom classes [23] [24] . It is not surprising, therefore, that 30% of patients remain refractory to current treatments and critical needs remain to be met in the management of schizophrenia 25 . Brilaroxazine (RP5063), a promising therapeutic presently 32 treatment-emergent adverse events (TEAEs) were observed, with orthostatic hypotension (n = 6), nausea (n = 4), and dizziness (n = 4) being the most common. Neither food nor race influenced the safety results. In the multipledose study, brilaroxazine was well tolerated at doses from 10 to 100 mg. Seventy-five TEAEs were reported, with somnolence (n = 16) and akathisia (n =12) the most frequent. Two serious adverse events (akathisia) were reported only at the 100-mg dose. These studies did not see any clinically significant changes in glucose or prolactin levels, lipid profiles, weight, or electrocardiographic recordings. In both studies, all TEAEs resolved, and none led to withdrawal or death.
Pharmacokinetics
These studies provided for an initial assessment of the pharmacokinetic profile ( Table 2 , Figures 1 and 2 ) 30, 31 . In the single-dose study, plasma concentrations of brilaroxazine peaked at about 5 hours after dosing and then declined in a biphasic manner with a terminal half-life of approximately 40 to 50 hours. Mean C max and area under the curve (AUC) ∞ increased in a linear, dose-proportional fashion over the dosing range. Food did provide a slight increase in drug absorption as seen in C max (reaching a median T max of 6 hours post-dose), and AUC ∞ , representative of drug exposure. Neither race (Japanese versus Caucasian) nor CYP2D6 genotype appear to influence the pharmacokinetic profile.
In the multiple-dose study, C max and AUC ss also increased in a linear, dose-proportional manner from 10 to 100 mg, (20.2 ng/mL to 195.0 ng/mL, respectively for C max and from 314.0 hour*ng/mL to 3538.0 hour*ng/mL, respectively for AUC ss ). Mean C max was reached at a median time of 4 to 5 hours post-dose across all dose levels. Mean trough concentrations indicate that by 120 hours of daily dosing steady-state was approached. The half-life (ranging from 55 to 71 hours) was similar across all the dose levels.
Pharmacodynamic Assessment
Since the multiple-dose study was conducted in stable patients with schizophrenia, an initial pharmacodynamic evaluation was undertaken to provide insight into the clinical activity of brilaroxazine 31 . While brilaroxazine (pooled doses) did not show significance versus placebo in PANSS Total Score or individual subscales specific to change from baseline for each visit, it did show promising signals of activity in several secondary analyses. These included significant improvements (P<0.05) versus placebo in (1) PANSS Marder-derived Depression/ Anxiety and Impulsivity/Hostility Factors and (2) PANSS secondary analysis for Positive Subscale Scores of patients with a baseline PANSS score of 50 or higher (Figure 3 ) [31] [32] [33] . Furthermore, improvements in Trails A and Trails B Test results were observed for patients treated in the 50 mg dose group (Days 5, 10, and 16).
under clinical development, possesses a broad in vitro pharmacology profile against dopamine (D) and serotonin (5-HT) receptors that underlie the pathogenesis of schizophrenia and related neuropsychiatric disorders. This compound possesses a high binding affinity for the D 2/3/4 and 5-HT 1A/2A/2B/7 receptors and moderate binding affinity for the 5-HT 6 and nicotinic acetylcholine (α 4 β 2 ) receptors, along with the serotonin transporter 26, 27 . It displays partial agonist activity at the D 2/3/4 and 5-HT 1A/2A receptors, and antagonist activity at the 5-HT 2B/6/7 receptors 26 .
Preclinical studies have established the activity, pharmacokinetics, and safety profile of brilaroxazine in animals (unpublished). Rodent models of pharmacologicinduced behaviors associated with schizophrenia have demonstrated that brilaroxazine limits both psychosis and cognitive symptoms 28, 29 .
Considering the preclinical profile and unmet needs with present treatment options, Reviva Pharmaceuticals, Inc., proceeded to develop brilaroxazine for schizophrenia and schizoaffective disorders. Over this past year, investigators published four clinical research papers that describe the Phase 1 and 2 experience with this compound. The following discussion examines the safety, efficacy, pharmacokinetic, and pharmacodynamic results seen in Phase 1 studies (single-dose and multiple doses) and the Phase 2 trial, along with their implications.
Phase 1 Studies Provide a Promising Safety,

Pharmacokinetic, and Pharmacodynamic Profile
Two Phase 1 studies were undertaken to define the initial clinical experience 30, 31 . The first-in-human study involved an ascending single-dose study, and the first-inpatient study involved a multiple-dose ascending study over 10 days. Both studies characterized the initial safety and pharmacokinetic profiles in normal healthy volunteers , chronic, all types with Total Positive and Negative Syndrome Scale [PANSS] score < 90 points). Also, the multiple-dose study provided initial insight into the pharmacodynamic effects in stable patients.
The single-dose was a dose-escalation study recruiting 24 individuals, with 23 completing the full evaluation. Initially, it examined patient cohorts receiving individual doses of 10 and 15 mg fasting, followed by a food-effect group (food versus fasting, crossover) with 15 mg dose. The multiple-dose study examined multiple doses of 10, 20, 50, and 100 mg given with food over ten days in 32 randomized patients.
Safety
In each study, brilaroxazine displayed an encouraging safety profile (Tables 1) 30, 31 . In the single-dose study, However, since treatment was for 10-days and in stable patients, it was not surprising that inconsistencies in its effect across doses for Clinical Global Improvement (CGI) and Bond and Lader visual analog scales precluded any meaningful conclusions from these determinations.
Phase 2 Trial Adds to the Safety, Efficacy and Pharmacokinetics/Pharmacodynamic Picture
The Phase 2 (REFRESH; NCT01490086) evaluation was conducted in patients with acute exacerbations of schizophrenia or schizoaffective disorder to evaluate the efficacy, safety, tolerability, and pharmacokinetics of brilaroxazine versus placebo 26 . This 28-day, multicenter, placebo-controlled, double-blind study randomized 234 subjects to brilaroxazine (15, 30, or 50 mg); aripiprazole (15 mg); or placebo (ratio, 3:3:3:1:2) once daily. The primary endpoint was changed from baseline to Day 28/End-ofTreatment of PANSS total score, a standardized, validated drug sensitive instrument that is commonly used in registration trials to assess positive, negative, and cognitive symptoms in patients with schizophrenia were used as a response factor. Study participants were dosed daily following an overnight fast before breakfast for 28 days and followed up 1 week after the last dose. Patients were required to remain in the testing facility for the study duration to ensure accurate dosing and sample time collection. Safety analysis involved the collection and analysis of adverse events, laboratory, and discontinuation rates. Plasma samples were obtained from patients treated with brilaroxazine.
Clinical Efficacy
The primary analysis of PANSS Total (Figure 4) 
Safety
The most common TEAEs for brilaroxazine were insomnia (23.42%) and agitation (12.57%). Body weight, electrocardiogram, or incidence of orthostatic hypotension did not display any significant changes. Interestingly, blood glucose, lipid profiles, and prolactin levels all decreased rather than increased, unlike that seen with other atypical psychotropics. Discontinuation for any reason for brilaroxazine (14%, 25%, 12%) was much lower than for placebo (26%) and aripiprazole (35%). There were no side effects related dropouts in brilaroxazine dose groups 15 mg and 30 mg. The highest dose (50mg) of brilaroxazine showed only 2% side effect related dropouts, whereas aripiprazole 15 mg showed 10%.
Pharmacokinetic and Pharmacodynamic Analyses and Models
Analysis of Phase 2 trial data involving patients with schizophrenia and schizoaffective disorder was undertaken to define: (1) the pharmacokinetics of brilaroxazine; and (2) the pharmacokinetic/ pharmacodynamic relationships of brilaroxazine utilizing the improvement in the primary endpoint (Total PANSS) 34 . This analysis was performed to complement the pharmacokinetic profile and to provide useful data to guide dose planning in patients with acute exacerbations of schizophrenia or schizoaffective disorder for the Phase 3 trial.
During the Phase 2 trial, five blood samples (10 mL) were collected from each patient pre-dose at baseline and at four other time intervals, using sampling blocks of time with a predesignated number of patients per block, so samples were obtained encompassing the whole dosing period up to 220 hours after the last dose 26 . Additional data collected, included covariates (body weight, body mass index, age, sex, smoking, concomitant drug use, race/ ethnicity, geographic area of the clinical site, and creatinine clearance [Cockcroft Gault] as a surrogate for glomerular filtration rate. The population pharmacokinetic analysis involved the development of 1-and 2-compartment models and the evaluation of the impact of co-variates utilizing bootstrap techniques. The population pharmacodynamic analysis included the development of an Emax model for total PANSS from the Phase 2 trial as the response factor against cumulative AUC 34 .
The pharmacokinetic analysis identified a 1-compartmental model incorporating the covariate of body mass index as the optimum construct for this sparse data set (Table 3 ). The fixed-effect parameters were, oral clearance (Cl/F), 5.11 ± 0.11 L/h and volume of distribution (V/F), 328.00 ± 31.40 L; absorption constant (ka) 0.41 ± 0.17 h-1; and lag time (t-lag) of 0.41 ± 0.02. A statistical evaluation showed that the brilaroxazine pharmacokinetic profile was linear. The calculated half-life was 44.5 hours like that seen in the earlier studies. Thus, the parameters predicted from this analysis were consistent with those obtained previously in normal healthy volunteers and patients with stable schizophrenia using a traditional pharmacokinetic approach ). An E max model ( 
Safety Profile Begins to Fulfill Unmet Needs for Schizophrenia
The initial Phase 1 and 2 studies with brilaroxazine reflect an encouraging safety profile 26, 30, 31 . It is essential to put this safety profile into perspective relative to the sideeffect profiles of other available treatments, all of which can further complicate health status. When reviewing the data, several themes emerge relative to safety and tolerability.
Theme 1: Brilaroxazine Appeared to Be Well Tolerated
The overall incidence rates of TEAEs with brilaroxazine were low and more prevalent with higher doses (50 and 100 mg). These studies did not find any of these TEAEs were associated with any severe morbidity, mortality, or study withdrawals. Patient compliance was very favorable with discontinuation in the Phase 2 trial (12-25%), either lower or similar to placebo (26%) and lower than a positive control, aripiprazole (35%) 26 .
Theme 2: Issues Exist with Current Treatments that Warrant Newer Alternatives
When considering the two classes of current treatment, typical agents block dopamine receptors, mainly D 2 , leading to extrapyramidal symptoms and hyperprolactinemia 11, 13 . Treatment with these antipsychotics can lead to a decrease in or loss of sexual interest directly through D 2 receptor antagonism and indirectly through hyperprolactinemia 10 . These side effects can severely limit compliance, which has been reported as low as 40% to 50% 11, 35, 36 . These agents can also contribute to unintentional weight gain [37] [38] [39] .
Atypical agents, on the other hand, exert antagonistic activity on 5-HT, specifically 5-HT 2A , along with D 2 . These agents are also limited by their side effects 13, 40 . Furthermore, atypical agents have been linked with weight gain and type 2 diabetes mellitus, leading to a US Food and Drug Administration warning in the package inserts of agents in this class [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] . Dibenzodiazepine-derived atypical agents (e.g., clozapine, olanzapine, and quetiapine) have also produced elevated serum triglyceride levels, with clozapine and olanzapine showing increased cholesterol levels after 8 weeks of treatment 44, 45 . Direct cardiovascular effects have been noted including an increased QTc (ziprasidone), myocarditis (clozapine), and worsening hypertension control (aripiprazole) [46] [47] [48] [49] [50] . Finally, increased prolactin levels have been reported with amisulpride and risperidone, and retrograde ejaculation and priapism have been seen with clozapine, risperidone, and olanzapine [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] .
With brilaroxazine, metabolic parameters (e.g., blood glucose, lipid profiles, and prolactin) did not change significantly in these studies. There were no reports of sexual dysfunction. No significant changes were seen in body weight, clinical laboratories, electrocardiogram, or incidence of orthostatic hypotension, as compared with placebo, potentially providing a considerable advantage over currently existing medications.
Theme 3: Comorbidities Limit Clinician Chose and Define Further Unmet Needs
Furthermore, patients with schizophrenia experience multiple comorbidities at a higher rate than normal healthy individuals 51 . These factors include lifestyle (e.g., high smoking prevalence, high-fat diet), neglect of personal care, and barriers for treatment of ongoing conditions 13 . Between 40% and 60% of patients with schizophrenia are overweight, and their baseline cardiometabolic and cardiovascular risks are higher than those of the general population 13, 52 . Psychosis is associated with reduced sexual interest, activity, and satisfaction 53, 54 . Furthermore, direct cardiovascular effects present an even greater concern in older patients.
Additionally, between 30% and 50% of patients with NDDs (Alzheimer's disease, Parkinson's disease, Parkinson's spectrum disorders, and Huntington's disease) suffer from psychosis [5] [6] [7] 55 . These neurological illnesses erode the patient's cognition and motor skills, along with their very perception of reality, causing hallucinations and delusions, agitation and aggression, and other related phenomena 56, 57 . The characteristics and severity of psychotic and behavioral symptoms in neurological diseases may differ from schizophrenia possibly due to more 5-HT dysfunction than dopamine 55, [58] [59] [60] [61] . Published experience involving NDDs with typical and atypical agents appear limited. Side effects from these treatments can potentially further complicate the neurologic condition, as well as contributing to poor compliance.
Hence, these underlying conditions can quickly limit clinician choice when considering the side-effect profiles of available medications and clearly define the need for newer alternatives 62 . The safety profile that displays no significant cardiovascular, cardiometabolic, laboratory, and neurologic effects may offer clinicians an alternative to fulfill present unmet needs related to patient safety and tolerability that limit persistency with therapy. This safety profile of brilaroxazine, along with its quick onset and efficacy profile, should enable the clinician to manage acute symptoms effectively without the need to switch to another drug for the long-term treatment of schizophrenia, where compliance can be poor.
Pharmacokinetic
Profile Provides for a Straightforward Once-Daily Dosing Schedule
The parameters predicted from the population analysis were similar to those obtained from previous brilaroxazine Phase 1 studies in normal healthy volunteers and patients with stable schizophrenia using a traditional pharmacokinetic approach 34 . The results from these studies offer valuable insights into the direction of dosing regimen design in future stages of clinical investigation. When reviewing the data from these two papers, several key themes emerge from these studies regarding the pharmacokinetic profile of brilaroxazine. Both the Phase 1 study data and Phase 2 analysis reflected linear, dose-proportional increases in exposure with dose and with no evidence of time dependency. Of significant note, the exposure of brilaroxazine as measured by C max and AUC increased in direct proportionality to drug dose irrespective of the population being used in the studies (healthy volunteers, stable schizophrenic patients or schizophrenic patients with acute exacerbations of schizophrenia or schizophrenic disorder).
Theme 2: The Lack of Accumulation Translates to No Need for Dose Titration.
In Phase 1 multi-dose study, drug levels approached steady-state after 120 h (5 days) of daily dosing, with doses between 10 and 100 mg with maximum steady-state concentrations of 70.1 and 696 ng/mL and AUC ss of 1361 and 12526 ng*h/mL at the 10 and 100 mg dose, respectively. The lack of excessive accumulation translates to a potential clinical advantage of no need for titration of therapy, as may be the case with other atypical antipsychotics (e.g., aripiprazole) 63 .
Theme 3: The Long Half-life Translates to Once-Daily Dosing and Coverage of a Missed Dose
The half-life ranged from 40 h to 71.9 h from the three studies: (1) 40-50 h in single-dose; (2) 55-71.9 h in the multiple-dose; and (3) 44.5 h from the Phase 2 population modeling. Moreover, since brilaroxazine is a low clearance compound (Cl/F approx. 10% of hepatic blood flow), the similarity of the half-life between a single dose and after the 10th administration of a daily dosage regimen, together with AUC ss predicted from single-dose data, would confirm the lack of time dependency. Nevertheless, the half-life of over 40 h translates easily to a once-daily dosing schedule, as well as being of clinical importance for the schizophrenic patient population, since medication adherence and missing doses of shorter half-life drugs can be a clinical issue leading to destabilization of clinical control 14 and poor long-term functional outcomes in the treatment of schizophrenia. With brilaroxazine, if a patient misses a single dose or two, sufficient plasma concentrations remain for clinical control.
Theme 4: The Lack of Pharmacokinetic Differences Translates to Straightforward Dosing Across Populations
An examination of the pharmacokinetics of brilaroxazine from the studies revealed that the pharmacokinetics of brilaroxazine were independent of race, ethnicity, health status, and type of schizophrenia disorder treated. These observations mean that no dose adjustments are needed based on the patient population.
Conclusions
Both treatment and comorbidity factors complicate schizophrenia management. Safety, tolerability, breadth of symptom coverage, and simplicity of dosing limit current treatments. Furthermore, multiple comorbidities, including those with NDDs, make the clinician's choice difficult. These all present numerous unmet medical needs.
The initial clinical experience of brilaroxazine in healthy volunteers and schizophrenia and schizoaffective disorder patients define this compound as a promising addition to the treatment armamentarium of this condition. Both healthy volunteers and patients tolerated brilaroxazine well in both Phase 1 and 2 studies. It did not produce any cardiometabolic, cardiovascular, prolactin, or neurologic side effects, which would complicate current treatments. Early activity was observed in results from the Phase 1 study after 10-days of dosing in stable patients and efficacy was seen in the findings from the Phase 2 trial, as brilaroxazine demonstrated significance versus placebo in Total PANSS Score at Day 28 as compared to baseline. The pharmacokinetics proved to be highly predictable and consistent between Phase 1 and 2 studies, participant type (healthy volunteer, patient), and racial characteristics (Black, Caucasian, Indian, and Japanese). Pharmacokinetic analyses showed substantive and relatively rapid oral absorption, linear, dose proportional increases in C max and AUC, lack of excessive accumulation, and a relatively long terminal half-life over 40 hours. These findings translate to a straightforward once-daily dosing regimen with no need for titration or adjustments based on racial characteristics. These characteristics set the stage for further evaluation in Phase 3, which is planned to start in soon.
